Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

EDUARDO MUÑOZ BLANCO2026-01-292026-01-29201810.1186/s12974-018-1060-52-s2.0-85040741073https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/28801Cellular and Molecular NeuroscienceImmunologyNeurologyNeuroscience (all)Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptorresearch article